Challenges Associated With Molecular Targeted Therapies in Lung Cancer

Clinical Pearls

Thomas J. Lynch, MD, director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital at Yale-New Haven, discusses challenges associated with treating patients with lung cancer with molecular targeted therapies.

• It is important for an oncologist to know when use (or switch) molecular targeted therapies in relation to a patient’s degree of progression.
• Dealing with drug side effects remains a challenge. During later lines of treatment, patients are typically less tolerant of side effects.